消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2020 JSGE循证临床实践指南：炎症性肠病

2021-04-22 日本胃肠病学会 J Gastroenterol.2021 Apr 22.

炎症性肠病

2021年4月，日本胃肠病学会(JSGE)炎症性肠病临床实践指南2020年版英文版发布。本文是对2016年版指南的更新主要针对炎症性肠病的诊断和治疗提供循证指导建议。

中文标题：

2020 JSGE循证临床实践指南：炎症性肠病

英文标题：

Evidence-based clinical practice guidelines for inflammatory bowel disease 2020

发布机构：

日本胃肠病学会

发布日期：

2021-04-22

简要介绍：

2021年4月，日本胃肠病学会(JSGE)炎症性肠病临床实践指南2020年版英文版发布。本文是对2016年版指南的更新主要针对炎症性肠病的诊断和治疗提供循证指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 JSGE循证临床实践指南：炎症性肠病.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ed95a1c002092977, title=2020 JSGE循证临床实践指南：炎症性肠病, enTitle=Evidence-based clinical practice guidelines for inflammatory bowel disease 2020, guiderFrom=J Gastroenterol.2021 Apr 22., authorId=0, author=, summary=2021年4月，日本胃肠病学会(JSGE)炎症性肠病临床实践指南2020年版英文版发布。本文是对2016年版指南的更新主要针对炎症性肠病的诊断和治疗提供循证指导建议。, cover=https://img.medsci.cn/202158/1620486481875_2020535.jpg, journalId=0, articlesId=null, associationId=1109, associationName=日本胃肠病学会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Apr 22 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年4月，日本胃肠病学会(JSGE)炎症性肠病临床实践指南2020年版英文版发布。本文是对2016年版指南的更新主要针对炎症性肠病的诊断和治疗提供循证指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1125, tagName=炎症性肠病)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1125, guiderKeyword=炎症性肠病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6587, appHits=297, showAppHits=0, pcHits=1057, showPcHits=6290, likes=2, shares=32, comments=13, approvalStatus=1, publishedTime=Sat May 08 23:28:46 CST 2021, publishedTimeString=2021-04-22, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat May 08 23:08:06 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 07:12:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 JSGE循证临床实践指南：炎症性肠病.pdf)])
2020 JSGE循证临床实践指南：炎症性肠病.pdf
下载请点击：
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1230491, encodeId=570a1230491be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0158135594, createdName=ms3000001902565087, createdTime=Mon Jul 04 15:44:05 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075648, encodeId=188610e564898, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:06:49 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073056, encodeId=fff410e3056fb, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da414779546, createdName=812018439, createdTime=Tue Nov 23 02:20:41 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014188, encodeId=da3b10141889c, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Sep 03 08:22:05 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008657, encodeId=cb7f100865eb7, content=必须好啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:46:47 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2022-07-04 ms3000001902565087

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1230491, encodeId=570a1230491be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0158135594, createdName=ms3000001902565087, createdTime=Mon Jul 04 15:44:05 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075648, encodeId=188610e564898, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:06:49 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073056, encodeId=fff410e3056fb, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da414779546, createdName=812018439, createdTime=Tue Nov 23 02:20:41 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014188, encodeId=da3b10141889c, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Sep 03 08:22:05 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008657, encodeId=cb7f100865eb7, content=必须好啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:46:47 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-12-01 14号射手

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1230491, encodeId=570a1230491be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0158135594, createdName=ms3000001902565087, createdTime=Mon Jul 04 15:44:05 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075648, encodeId=188610e564898, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:06:49 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073056, encodeId=fff410e3056fb, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da414779546, createdName=812018439, createdTime=Tue Nov 23 02:20:41 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014188, encodeId=da3b10141889c, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Sep 03 08:22:05 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008657, encodeId=cb7f100865eb7, content=必须好啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:46:47 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-11-23 812018439

    好文章

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1230491, encodeId=570a1230491be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0158135594, createdName=ms3000001902565087, createdTime=Mon Jul 04 15:44:05 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075648, encodeId=188610e564898, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:06:49 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073056, encodeId=fff410e3056fb, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da414779546, createdName=812018439, createdTime=Tue Nov 23 02:20:41 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014188, encodeId=da3b10141889c, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Sep 03 08:22:05 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008657, encodeId=cb7f100865eb7, content=必须好啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:46:47 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-09-03 小强的姣宝

    好文章！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1230491, encodeId=570a1230491be, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0158135594, createdName=ms3000001902565087, createdTime=Mon Jul 04 15:44:05 CST 2022, time=2022-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075648, encodeId=188610e564898, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160929/IMG57EBFB2F217CC3250.jpg, createdBy=e8381958770, createdName=14号射手, createdTime=Wed Dec 01 02:06:49 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073056, encodeId=fff410e3056fb, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da414779546, createdName=812018439, createdTime=Tue Nov 23 02:20:41 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1014188, encodeId=da3b10141889c, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGva1VbaRlGicxU4WwvgCPQ7TqUvNHSESK8A0IWbeg6KTUIKopMYZpBQTz6HhEgfPpFTqyuIOI2nQ/132, createdBy=7a715205116, createdName=小强的姣宝, createdTime=Fri Sep 03 08:22:05 CST 2021, time=2021-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008657, encodeId=cb7f100865eb7, content=必须好啊 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Aug 17 11:46:47 CST 2021, time=2021-08-17, status=1, ipAttribution=)]
    2021-08-17 DR.Fu SIR

    必须好啊

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2021 ECCO指南：炎症性肠病感染的预防，诊断和管理

欧洲克罗恩病和结肠炎组织(ECCO,European Cron&#039;s and Colitis Organisation) · 2021-03-17

中国炎症性肠病病理诊断专家指导意见

中华医学会消化病学分会炎症性肠病学组 · 2021-01-16

中国炎症性肠病影像检查及报告规范专家指导意见

中国消化科相关专家小组（统称） · 2021-01-16

中国炎症性肠病营养诊疗共识

中华医学会肠外肠内营养学分会(CSPEN,Chinese Society for Parenteral and Enteral Nutrition) · 2021-01-15

2020 ESPGHAN意见书：单基因型炎症性肠病的临床基因组学诊断

欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition) · 2020-12-16

中国炎症性肠病消化内镜诊疗共识

中国医药教育协会 · 2020-10-30

拓展阅读

2014年加拿大炎症性肠病（IBD）与静脉血栓防治共识意见：加拿大胃肠病学会

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2014-03-01

2014 ESPGHAN儿童和青少年炎症性肠病诊断的波尔图标准（修订版）

欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition) · 2014-06-10

2014 CAG立场声明：应用巯嘌呤类药物治疗炎症性肠病

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2014-07-04

2015 ASGE指南：内镜检查在炎症性肠病中的作用

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2015-03-20

2016 建立我国炎症性肠病诊治中心质量控制指标的共识

中华医学会消化病学分会炎症性肠病学组 · 2016-07-30

2017 IG-IBD临床实践指南：应用糖皮质激素和免疫抑制药物治疗炎症性肠病

意大利炎症性肠病研究组(IG-IBD,Italian Group for the Study of Inflammatory Bowel Disease) · 2017-01-25